Show simple item record

dc.contributor.authorBarreto G.E.
dc.contributor.authorIarkov A.
dc.contributor.authorMoran V.E.
dc.date.accessioned2020-09-02T22:13:00Z
dc.date.available2020-09-02T22:13:00Z
dc.date.issued2015
dc.identifier10.3389/fnagi.2014.00340
dc.identifier.citation7, JAN, -
dc.identifier.issn16634365
dc.identifier.urihttps://hdl.handle.net/20.500.12728/3692
dc.descriptionParkinson's disease (PD) is a progressive neurodegenerative disorder, which is characterized by neuroinflammation, dopaminergic neuronal cell death and motor dysfunction, and for which there are no proven effective treatments. The negative correlation between tobacco consumption and PD suggests that tobacco-derived compounds can be beneficial against PD. Nicotine, the more studied alkaloid derived from tobacco, is considered to be responsible for the beneficial behavioral and neurological effects of tobacco use in PD. However, several metabolites of nicotine, such as cotinine, also increase in the brain after nicotine administration. The effect of nicotine and some of its derivatives on dopaminergic neurons viability, neuroinflammation, and motor and memory functions, have been investigated using cellular and rodent models of PD. Current evidence shows that nicotine, and some of its derivatives diminish oxidative stress and neuroinflammation in the brain and improve synaptic plasticity and neuronal survival of dopaminergic neurons. In vivo these effects resulted in improvements in mood, motor skills and memory in subjects suffering from PD pathology. In this review, we discuss the potential benefits of nicotine and its derivatives for treating PD. © 2015 Barreto, Iarkov and Moran.
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.subjectAkt(PKB)
dc.subjectBeta-amyloid
dc.subjectCotinine
dc.subjectNicotine
dc.subjectParkinson disease
dc.subjectSynucleinopathies
dc.subject3 (2,4 dimethoxybenzylidene)anabaseine
dc.subjectcotinine
dc.subjectdrug metabolite
dc.subjectnicotine
dc.subjectdopaminergic nerve cell
dc.subjectdrug effect
dc.subjectdrug safety
dc.subjecthuman
dc.subjectmemory
dc.subjectmotor performance
dc.subjectnerve cell plasticity
dc.subjectnervous system inflammation
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectParkinson disease
dc.subjectprotein aggregation
dc.subjectReview
dc.titleBeneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease
dc.typeReview


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record